![](https://d3ilqtpdwi981i.cloudfront.net/xRhWjWwdgvuBH1Qlb7XExvVIoHY=/0x51:371x531/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/d0/5d/16/d05d16c1-3e07-4cc2-a3db-15f8c3c1ceb7/BHSF%20Pineapple%20Logo%20%28Imported%20Works%29.png)
Background: Talazoparib is a poly (adenosine diphosphate-ribose) polymerase inhibitor approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative, locally advanced or metastatic breast cancer (LA/mBC), with approval based on the EMBRACA trial. To date, there are no published data on talazoparib use in the real-world United States (USA) setting.
Patients and methods: Characteristics, treatment patterns, and clinical outcomes of real-world US patients with gBRCAm HER2-negative LA/mBC treated with talazoparib monotherapy were collected via retrospective chart review and summarized using descriptive statistics.
Results: Among 84 eligible patients, 35.7% had hormone receptor-positive tumors and 64.3% had triple-negative LA/mBC (TNBC). At talazoparib initiation, 29.8% had ECOG PS of ≥2 and 19.0% had brain metastasis. Mutations in gBRCA1 or 2 were detected among 64.3% and 35.7% of patients, respectively. Talazoparib was given as 1st-line therapy in 14.3% of patients, 2nd-line in 40.5%, and 3rd- or 4th-line in 45.2%. Median time to talazoparib treatment failure was 8.5 months (95% CI, 8.0-9.7), median progression-free survival was 8.7 months (95% CI, 8.0-9.9), the median time from initiation to chemotherapy was 12.2 months (95% CI, 10.5-20.1), and the overall response rate was 63.1%. No differences in clinical outcomes were observed between patients with HR-positive/HER2-negative LA/mBC and patients with TNBC by using unadjusted statistical comparisons. Brain metastasis and ECOG PS ≥2 at talazoparib initiation were associated with treatment failure and progression or mortality.
Conclusion: Overall, talazoparib clinical outcomes in this real-world population are consistent with findings from EMBRACA.
Savill, K. M. Z., Ivanova, J., Asgarisabet, P., Falkenstein, A., Balanean, A., Niyazov, A., Ryan, J. C., Kish, J., Gajra, A., & Mahtani, R. L. (2023). Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer. The oncologist, 28(5), 414–424. https://doi.org/10.1093/oncolo/oyad021
The Author(s) 2023. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.